At the time of writing, 4D Molecular Therapeutics Inc [FDMT] stock is trading at $18.35, down -0.92%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The FDMT shares have gain 27.43% over the last week, with a monthly amount drifted -12.66%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
4D Molecular Therapeutics Inc [NASDAQ: FDMT] stock has seen the most recent analyst activity on April 15, 2024, when Barclays initiated its Overweight rating and assigned the stock a price target of $459. Previously, Barclays started tracking the stock with Overweight rating on April 15, 2024, and set its price target to $45. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $25 on October 26, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $32 as its price target on October 24, 2023. Leerink Partners upgraded its rating to Outperform for this stock on October 18, 2023, but kept the price target unchanged to $24. In a note dated July 05, 2023, Chardan Capital Markets initiated an Buy rating and provided a target price of $30 on this stock.
For the past year, the stock price of 4D Molecular Therapeutics Inc fluctuated between $9.44 and $36.25. Currently, Wall Street analysts expect the stock to reach $44.57 within the next 12 months. 4D Molecular Therapeutics Inc [NASDAQ: FDMT] shares were valued at $18.35 at the most recent close of the market. An investor can expect a potential return of 142.89% based on the average FDMT price forecast.
Analyzing the FDMT fundamentals
According to 4D Molecular Therapeutics Inc [NASDAQ:FDMT], the company’s sales were 21.99M for trailing twelve months, which represents an -97.75% plunge. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -5.91%, Pretax Profit Margin comes in at -5.11%, and Net Profit Margin reading is -5.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.48 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.94 points at the first support level, and at 17.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.05, and for the 2nd resistance point, it is at 19.74.
Ratios To Look Out For
It is important to note that 4D Molecular Therapeutics Inc [NASDAQ:FDMT] has a current ratio of 32.65. Further, the Quick Ratio stands at 32.65, while the Cash Ratio is 16.8. Considering the valuation of this stock, the price to sales ratio is 43.14, the price to book ratio is 1.56.
Transactions by insiders
Recent insider trading involved Bizily Scott, Chief Legal Officer, that happened on Jul 16 ’24 when 1750.0 shares were sold. Chief Legal Officer, Bizily Scott completed a deal on Jul 11 ’24 to sell 1996.0 shares. Meanwhile, Chief Executive Officer Kirn David sold 12923.0 shares on Jul 10 ’24.
